Text Size

Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

This study has been withdrawn prior to enrollment.
(PI (Prof. Slavin) not longer work at Hadassah)
Sponsor:
Collaborator:
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00148993
First received: September 7, 2005
Last updated: April 7, 2011
Last verified: July 2005
History of Changes
  Purpose

The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in patients with micro-metastatic disease and/or in patients at high risk disease progression. The present study will use allogeneic tumor cell lines for tumor cell vaccines that share MHC determinants with the patient aiming to overcome possible restriction of antigen presentation.


Condition Intervention Phase
Metastatic Solid Tumors
 Biological: Tumor Cell Vaccine
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Investigate the feasibility of anti-tumor immune response by allogeneic tumor cell vaccine using tumor cells that share MHC determinants with the patient.

Secondary Outcome Measures:
  • Investigate the feasibility of immune responses against cancer cells by combining allogeneic TCV with indomethacin, cimetidine, tetanus and rIL-2.

Estimated Enrollment: 100
Study Start Date: July 1998
Estimated Study Completion Date: July 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with measurable metastatic disease or disease resistant to chemotherapy or with minimal residual disease at high risk to relapse.

Exclusion Criteria:

  • Karnofsky less than 60%. Unrelated condition requiring the use of any cytotoxic agents or immunosuppressive agents which may interfere with optimal immune response.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00148993

Locations
Israel
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Tel Aviv, Israel, 64239
Sponsors and Collaborators
Hadassah Medical Organization
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Investigators
Principal Investigator: shimon slavin, MD The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
  More Information

No publications provided

Responsible Party: Shimon Slavin MD, The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
ClinicalTrials.gov Identifier: NCT00148993     History of Changes
Other Study ID Numbers: 100798-HMO-CTIL
Study First Received: September 7, 2005
Last Updated: April 7, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
Tumor cell vaccine

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on May 16, 2013